In this edition of The Motley Fool's health care show Market Checkup, health care analysts David Williamson and Max Macaluso take a close look at AbbVie, the pharmaceutical company that was spun out of Abbott at the start of the year.
A deep dive into AbbVie, a brand new company with a long history.
Read Next
About the Author
Max is the Technology, Biopharma & Health Care Bureau Chief at Fool.com. Prior to joining the Fool, he completed a PhD in chemistry at the University of Cambridge and an MBA at the College des Ingenieurs.
Follow @TMFMassimo
Stocks Mentioned
Merck
NYSE: MRK
$106.88 (+0.00%) $+0.10
Pfizer
NYSE: PFE
$25.05 (0.00%) $0.04
Bristol Myers Squibb
NYSE: BMY
$54.34 (0.01%) $0.30
Gilead Sciences
NASDAQ: GILD
$124.55 (0.00%) $0.15
Regeneron Pharmaceuticals
NASDAQ: REGN
$780.08 (0.01%) $4.89
Abbott Laboratories
NYSE: ABT
$124.66 (0.00%) $0.18
Amgen
NASDAQ: AMGN
$330.15 (0.01%) $2.78
AbbVie
NYSE: ABBV
$230.80 (+0.00%) $+0.82
*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Advertisement